The use of high-sensitivity assays for C-reactive protein in clinical practice

Kiran Musunuru; Brian G. Kral; Roger S. Blumenthal; Valentin Fuster; Catherine Y. Campbell; Ty J. Gluckman; Richard A. Lange; Eric J. Topol; James T. Willerson; Milind Y. Desai; Michael H. Davidson; Samia Mora

doi:10.1038/ncpcardio1322

The use of high-sensitivity assays for C-reactive protein in clinical practice

Kiran Musunuru, Brian G. Kral, Roger S. Blumenthal, Valentin Fuster, Catherine Y. Campbell, Ty J. Gluckman, Richard A. Lange, Eric J. Topol, James T. Willerson, Milind Y. Desai, Michael H. Davidson, Samia Mora

Research output: Contribution to journal › Review article › peer-review

99 Scopus citations

Abstract

High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.

Original language	English (US)
Pages (from-to)	621-635
Number of pages	15
Journal	Nature Clinical Practice Cardiovascular Medicine
Volume	5
Issue number	10
DOIs	https://doi.org/10.1038/ncpcardio1322
State	Published - 2008

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1038/ncpcardio1322

Cite this

Musunuru, K., Kral, B. G., Blumenthal, R. S., Fuster, V., Campbell, C. Y., Gluckman, T. J., Lange, R. A., Topol, E. J., Willerson, J. T., Desai, M. Y., Davidson, M. H., & Mora, S. (2008). The use of high-sensitivity assays for C-reactive protein in clinical practice. Nature Clinical Practice Cardiovascular Medicine, 5(10), 621-635. https://doi.org/10.1038/ncpcardio1322

@article{64d885ae8363480c902b48e89c7652cf,

title = "The use of high-sensitivity assays for C-reactive protein in clinical practice",

abstract = "High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.",

author = "Kiran Musunuru and Kral, {Brian G.} and Blumenthal, {Roger S.} and Valentin Fuster and Campbell, {Catherine Y.} and Gluckman, {Ty J.} and Lange, {Richard A.} and Topol, {Eric J.} and Willerson, {James T.} and Desai, {Milind Y.} and Davidson, {Michael H.} and Samia Mora",

year = "2008",

doi = "10.1038/ncpcardio1322",

language = "English (US)",

volume = "5",

pages = "621--635",

journal = "Nature Clinical Practice Cardiovascular Medicine",

issn = "1743-4297",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - The use of high-sensitivity assays for C-reactive protein in clinical practice

AU - Musunuru, Kiran

AU - Kral, Brian G.

AU - Blumenthal, Roger S.

AU - Fuster, Valentin

AU - Campbell, Catherine Y.

AU - Gluckman, Ty J.

AU - Lange, Richard A.

AU - Topol, Eric J.

AU - Willerson, James T.

AU - Desai, Milind Y.

AU - Davidson, Michael H.

AU - Mora, Samia

PY - 2008

Y1 - 2008

N2 - High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.

AB - High-sensitivity assays that accurately measure levels of the inflammatory biomarker C-reactive protein have been proposed for use in assessments of risk for cardiovascular disease (CVD). A growing body of evidence supports recommendations for these tests in selected asymptomatic individuals deemed to be at intermediate risk of CVD according to traditional risk-factor assessments and who do not already warrant chronic treatment with aspirin and statin therapy. Data suggests that these high-sensitivity assays should be used in combination with measurements of LDL-cholesterol levels to assist risk stratification of selected patients for prevention of CVD.

UR - http://www.scopus.com/inward/record.url?scp=54849394100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54849394100&partnerID=8YFLogxK

U2 - 10.1038/ncpcardio1322

DO - 10.1038/ncpcardio1322

M3 - Review article

C2 - 18711404

AN - SCOPUS:54849394100

SN - 1743-4297

VL - 5

SP - 621

EP - 635

JO - Nature Clinical Practice Cardiovascular Medicine

JF - Nature Clinical Practice Cardiovascular Medicine

IS - 10

ER -

The use of high-sensitivity assays for C-reactive protein in clinical practice

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this